Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-23-022182
Filing Date
2023-05-15
Accepted
2023-05-15 16:02:12
Documents
46
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q evok-20230331.htm   iXBRL 10-Q 1041076
2 EX-10.1 evok-ex10_1.htm EX-10.1 46580
3 EX-31.1 evok-ex31_1.htm EX-31.1 17270
4 EX-31.2 evok-ex31_2.htm EX-31.2 17672
5 EX-32.1 evok-ex32_1.htm EX-32.1 11743
6 EX-32.2 evok-ex32_2.htm EX-32.2 12779
7 GRAPHIC img215256224_0.jpg GRAPHIC 31004
  Complete submission text file 0000950170-23-022182.txt   3629164

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT evok-20230331_lab.xml EX-101.LAB 245666
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT evok-20230331_pre.xml EX-101.PRE 168026
10 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT evok-20230331_cal.xml EX-101.CAL 24985
11 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT evok-20230331.xsd EX-101.SCH 29736
12 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT evok-20230331_def.xml EX-101.DEF 83482
40 EXTRACTED XBRL INSTANCE DOCUMENT evok-20230331_htm.xml XML 394177
Mailing Address 420 STEVENS AVENUE SUITE 370 SOLANA BEACH CA 92075
Business Address 420 STEVENS AVENUE SUITE 370 SOLANA BEACH CA 92075 858-345-1494
Evoke Pharma Inc (Filer) CIK: 0001403708 (see all company filings)

EIN.: 208447886 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36075 | Film No.: 23921816
SIC: 2834 Pharmaceutical Preparations